Suchen
ProQR Therapeutics NV
PRQRZur Watchlist hinzufügen
1.810USD
+0.060+3.43%
Handelsschluss 07/02, 13:00（ET）Kurse um 15 Minuten verzögert
194.96MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über ProQR Therapeutics NV Unternehmen
ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).
ProQR Therapeutics NV Informationen
BörsenkürzelPRQR
Name des UnternehmensProQR Therapeutics NV
IPO-datumSep 18, 2014
CEOde Boer (Daniel Anton)
Anzahl der mitarbeiter166
WertpapierartOrdinary Share
GeschäftsjahresendeSep 18
AddresseZernikedreef 9
StadtLEIDEN
BörseNASDAQ OMX - NASDAQ BASIC
LandNetherlands
Postleitzahl2333 CK
Telefon31881667000
Websitehttps://www.proqr.com/
BörsenkürzelPRQR
IPO-datumSep 18, 2014
CEOde Boer (Daniel Anton)
Führungskräfte von ProQR Therapeutics NV
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
--
Mr. Dinko Valerio, Ph.D.
Mr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Mr. Bart Filius
Mr. Bart Filius
Non-Executive Independent Director
Non-Executive Independent Director
150.00K
--
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
61.54K
--
Mr. Daniel Anton de Boer
Mr. Daniel Anton de Boer
Chief Executive Officer, Founder, Executive Director
Chief Executive Officer, Founder, Executive Director
--
--
Mr. Rene K. Beukema
Mr. Rene K. Beukema
Chief Corporate Development Officer, General Counsel, Executive Director
Chief Corporate Development Officer, General Counsel, Executive Director
--
--
Ms. Alison F. Lawton
Ms. Alison F. Lawton
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Theresa M. Heggie
Ms. Theresa M. Heggie
Non-Executive Director
Non-Executive Director
--
--
Ms. Sarah Kiely
Ms. Sarah Kiely
Vice President - Investor Relations and Corporate Communications
Vice President - Investor Relations and Corporate Communications
--
--
Ms. Sheila Sponselee
Ms. Sheila Sponselee
Chief People and Operations Officer
Chief People and Operations Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
--
Mr. Dinko Valerio, Ph.D.
Mr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Mr. Bart Filius
Mr. Bart Filius
Non-Executive Independent Director
Non-Executive Independent Director
150.00K
--
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
61.54K
--
Mr. Daniel Anton de Boer
Mr. Daniel Anton de Boer
Chief Executive Officer, Founder, Executive Director
Chief Executive Officer, Founder, Executive Director
--
--
Mr. Rene K. Beukema
Mr. Rene K. Beukema
Chief Corporate Development Officer, General Counsel, Executive Director
Chief Corporate Development Officer, General Counsel, Executive Director
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von ProQR Therapeutics NV?
Die fünf größten Anteilseigner von ProQR Therapeutics NV sind: Mr. Gerard Platenburg, Ph.D.
Wie viele Institutionen halten Anteile an ProQR Therapeutics NV (PRQR)?
Mit Stand vom 2026Q1 halten 122 Institutionen Anteile an ProQR Therapeutics NV, mit einem Gesamtmarktwert von etwa 38.34M, was 36.39% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -5670621.00 gestiegen.